The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions

被引:152
作者
Athyros, VG
Ganotakis, ES
Elisaf, M
Mikhailidis, DP
机构
[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Prop Dept Internal Med 2, Atherosclerosis Unit, Thessaloniki 55132, Greece
[2] Aristotle Univ Thessaloniki, Hippokrat Hosp, Prop Dept Internal Med 2, Metab Syndrome Unit, Thessaloniki 55132, Greece
[3] Univ Crete, Dept Internal Med, Rethimnon, Greece
[4] Univ Ioannina, Dept Internal Med, GR-45110 Ioannina, Greece
[5] UCL Royal Free & Univ Coll Med Sch, Royal Free Hosp, Dept Clin Biochem, London, England
关键词
glucose; insulin resistance; metabolic syndrome; prevalence; vascular risk; waist circumference;
D O I
10.1185/030079905X53333
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The prevalence of metabolic syndrome (MetS), using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and International Diabetes Federation (IDF) definitions, was compared in 9669 subjects, representing the Greek population. Results: The age-adjusted prevalence of NCEP ATP Ill-defined MetS was 24.5% whereas that of IDF-defined MetS was 43.4% (+77%, p < 0.0001). The majority (up to 69%) of older age groups had IDF-defined MetS. The calculated vascular event risk was low (6.1% and 7.2% using the Framingham and PROCAM calculation, respectively) in those with IDF-defined MetS when compared with those with NCEP ATP III MetS (11.3% and 13.7%, respectively) (p < 0.0001 for both comparisons). Conclusion: MetS could be considered as a 'normal' variant if it was present in the majority of the population. Moreover, the vascular risk associated with IDF-defined MetS could be low, raising cost-effectiveness issues. Alternatively, the new IDF definition may realistically reflect the current MetS epidemic. More studies are required to support or refute those interpretations.
引用
收藏
页码:1157 / 1159
页数:3
相关论文
共 10 条
  • [1] Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
  • [2] 2-S
  • [3] American Diabetes Association, 2004, Diabetes Care, V27 Suppl 1, pS5, DOI 10.2337/diacare.27.2007.S5
  • [4] Targeting vascular risk in patients with metabolic syndrome but without diabetes
    Athyros, VG
    Mikhailidis, DP
    Papageorgiou, AA
    Didangelos, TP
    Peletidou, A
    Kleta, D
    Karagiannis, A
    Kakafika, AI
    Tziomalos, K
    Elisaf, M
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 2005, 54 (08): : 1065 - 1074
  • [5] Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METSGREECE Multicentre Study
    Athyros, VG
    Mikhailidis, DP
    Papageorgiou, AA
    Didangelos, TP
    Ganotakis, ES
    Symeonidis, AN
    Daskalopoulou, SS
    Kakafika, AI
    Elisaf, M
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (11) : 1691 - 1701
  • [6] Balkau B, 1999, DIABETIC MED, V16, P442
  • [7] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [8] A comparison of the prevalence of the metabolic syndrome using two proposed definitions
    Ford, ES
    Giles, WH
    [J]. DIABETES CARE, 2003, 26 (03) : 575 - 581
  • [9] Cardiovascular morbidity and mortality associated with the metabolic syndrome
    Isomaa, B
    Almgren, P
    Tuomi, T
    Forsén, B
    Lahti, K
    Nissén, M
    Taskinen, MR
    Groop, L
    [J]. DIABETES CARE, 2001, 24 (04) : 683 - 689
  • [10] The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
    Lakka, HM
    Laaksonen, DE
    Lakka, TA
    Niskanen, LK
    Kumpusalo, E
    Tuomilehto, J
    Salonen, JT
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (21): : 2709 - 2716